North Branford, CT, United States of America

Peter A Blomgren

USPTO Granted Patents = 53 (Patent Applications = 15)

CIPO Patents = 7 (Patent Applications = 7)

EPO Patents = 27 (Patent Applications = 34)

Average Co-Inventor Count = 8.4

ph-index = 14

Forward Citations = 430(Granted Patents)

Forward Citations (Not Self Cited) = 267(Oct 12, 2025)

Location History:

North Branford, CT (US) (2009 - 2019)
Issaquah, WA (US) (2017 - 2024)

Company Filing History:

25 out of 919

Gilead Sciences, Inc.

patents

18 out of 30

Gilead Connecticut, Inc.

patents

6 out of 13

Cgi Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

53 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12358903 - FXR (NR1H4) modulating compounds (2025-07-15),

2. 12358887 - IKAROS Zinc Finger Family degraders and uses thereof (2025-07-15),

3. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

4. 12122764 - IKAROS zinc finger family degraders and uses thereof (2024-10-22),

5. 12053462 - Quinoline derivatives (2024-08-06),

6. 11897862 - IKAROS zinc finger family degraders and uses thereof (2024-02-13),

7. 11739065 - FXR (NR1H4) modulating compounds (2023-08-29),

8. 11578069 - Compounds for inhibition of α4 β7 integrin (2023-02-14),

9. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

10. 11247986 - FXR (NR1H4) modulating compounds (2022-02-15),

11. 11225473 - FXR (NR1H4) modulating compounds (2022-01-18),

12. 11224600 - Compounds for inhibition of alpha 4 beta 7 integrin (2022-01-18),

13. 11179383 - Compounds for inhibition of α4β7 integrin (2021-11-23),

14. 11174256 - Imidazopyridine derivatives (2021-11-16),

15. 11116760 - Quinoline derivatives (2021-09-14),

Title: Peter A. Blomgren: Innovator and Inventor in Pharmaceutical Advancements

Introduction

Peter A. Blomgren, based in North Branford, Connecticut, is a distinguished inventor with an impressive portfolio of 50 patents. His work primarily focuses on groundbreaking pharmaceutical compounds that have significant implications for the treatment of various diseases.

Latest Patents

Among his latest innovations are the "IKAROS zinc finger family degraders and uses thereof," which involves compounds that selectively bind to and facilitate the degradation of IKAROS Family Zinc Finger (IKZF) proteins, particularly IKZF2 (Helios). This innovative approach holds promise for developing medications aimed at treating diseases, including certain types of cancer. Another notable patent concerns "Quinoline derivatives," which describes a compound of a specific formula, as well as pharmaceutical compositions and therapeutic methods for addressing inflammatory diseases.

Career Highlights

Throughout his career, Peter has contributed to esteemed organizations such as Gilead Sciences, Inc. and Gilead Connecticut, Inc. His work in these companies has positioned him as a prominent figure in the pharmaceutical industry, particularly in the realm of medicinal chemistry and drug development.

Collaborations

Peter's innovative efforts have seen him collaborate with other talented professionals, including Kevin S. Currie and Jeffrey E. Kropf. These collaborations have enabled the advancement of research and development initiatives, fostering an environment that encourages creativity and innovation in drug discovery.

Conclusion

With a significant number of patents to his name, Peter A. Blomgren continues to make remarkable contributions to the field of pharmaceuticals. His inventions not only reflect his expertise and dedication but also pave the way for future advancements in medicine and therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.